EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische StudieVergleichsstudieOpen Access

Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE

Michael C Heinrich iD, Jean-Yves Blay iD, Hans Gelderblom iD, Suzanne George iD, Patrick Schöffski iD, Margaret von Mehren iD, John R Zalcberg, Robin L Jones iD, Yoon-Koo Kang iD, Albiruni Abdul Razak iD, Jonathan Trent iD, Steven Attia iD und 10 weitere

Journal of Clinical Oncology · 2025

DOI: 10.1200/jco-24-02818 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, 2025. Verfasst von Michael C Heinrich und 21 weiteren Autor:innen. Beteiligte Einrichtung: Portland VA Health Care System, Portland, OR. Hauptthemen laut MEDLINE: Gastrointestinal Stromal Tumors, Sunitinib, Gastrointestinal Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: BLRD VA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the INTRIGUE phase III trial (ClinicalTrials.gov identifier: NCT03673501 ), adult patients with advanced gastrointestinal stromal tumor previously treated with imatinib were randomly assigned 1:1 to ripretinib 150 mg once daily or sunitinib 50 mg once daily (4 weeks on/2 weeks off). In the primary analysis, overall survival (OS) was immature. In this study, we report the final planned analysis of OS (key secondary end point), progression-free survival (PFS) on third-line therapy (second PFS; prespecified exploratory end point), and long-term safety. Final OS analysis was prespecified to occur with approximately 200 and ≥145 events in the overall and KIT exon 11 intention-to-treat (ITT) populations, respectively. As of March 15, 2023, there were 211 and 151 OS events in the overall ITT and KIT exon 11 ITT populations, respectively. Median OS was similar between second-line ripretinib and sunitinib in both populations (overall, 35.5 v 31.5 months; KIT exon 11, 35.5 v 32.8 months). Median second PFS (on third-line therapy) for the overall ITT population was similar between the ripretinib and sunitinib arms (7.7 v 7.4 months). Safety was consistent with the primary analysis. OS from this analysis was similar between arms, and second PFS suggests that receiving ripretinib did not adversely affect the PFS of third-line therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal Stromal TumorsSunitinibGastrointestinal NeoplasmsAntineoplastic AgentsHumansMaleFemaleMiddle AgedAdultAgedProto-Oncogene Proteins c-kitProgression-Free SurvivalNaphthyridinesUrea

Substanzen

SunitinibripretinibProto-Oncogene Proteins c-kitAntineoplastic AgentsNaphthyridinesUrea

Autor:innen und Institutionen

  • Portland VA Health Care System, Portland, OR.
  • OHSU Knight Cancer Institute, Portland, OR.
  • Centre Léon Bérard, Lyon, France.
  • Leiden University Medical Center, Leiden, the Netherlands.
  • Dana-Farber Cancer Institute, Boston, MA.
  • University Hospitals Leuven, Department of General Medical Oncology, Leuven Cancer Institute, KU Leuven, Leuven, Belgium.

ORCID-Profile: Michael C Heinrich, Jean-Yves Blay, Hans Gelderblom, Suzanne George, Patrick Schöffski, Margaret von Mehren, Robin L Jones, Yoon-Koo Kang, Albiruni Abdul Razak, Jonathan Trent, Steven Attia, Axel Le Cesne, Kjetil Boye, César Sánchez, Paulina Cox, Rodrigo Ruiz-Soto, Sebastian Bauer

Förderung

  • BLRD VA

Zitieren

APA

Heinrich, M. C., Blay, J. Y., Gelderblom, H., George, S., Schöffski, P., von Mehren, M., Zalcberg, J. R., Jones, R. L., Kang, Y. K., Razak, A. A., Trent, J., Attia, S., Le Cesne, A., Boye, K., Goldstein, D., Sánchez, C., Siontis, B. L., Cox, P., Davis, E., …, & Bauer, S. (2025). Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE. Journal of Clinical Oncology. https://doi.org/10.1200/jco-24-02818

Vancouver

Heinrich MC, Blay JY, Gelderblom H, George S, Schöffski P, von Mehren M, et al. Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE. Journal of Clinical Oncology. 2025. doi:10.1200/jco-24-02818

BibTeX
@article{Heinrich2025,
  author = {Heinrich, Michael C and Blay, Jean-Yves and Gelderblom, Hans and George, Suzanne and Schöffski, Patrick and von Mehren, Margaret and Zalcberg, John R and Jones, Robin L and Kang, Yoon-Koo and Razak, Albiruni Abdul and Trent, Jonathan and Attia, Steven and Le Cesne, Axel and Boye, Kjetil and Goldstein, David and Sánchez, César and Siontis, Brittany L and Cox, Paulina and Davis, Erika and Sherman, Matthew L and Ruiz-Soto, Rodrigo and Bauer, Sebastian},
  title = {Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  doi = {10.1200/jco-24-02818}
}
Kostenlos starten →